ReviewFrontiers in immunology2025
Beneficial effects of food-medicine homologous herbs for patients with diabetic kidney disease.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Natural product therapy in diabetic kidney disease: emerging multiomics-mediated signalling pathway and molecular target.Chinese medicine · 2026Review
- Linking Gut Microbiota, Mitochondrial Redox Dysfunction, and Ferroptosis in Cardiometabolic Diseases: A Narrative Review of Mechanistic Evidence and Redox-Targeted Interventions.Antioxidants (Basel, Switzerland) · 2026Review
- Mechanisms of Macrophage Glycolytic Reprogramming and Interventional Effects of Traditional Chinese Medicine on Renal Fibrosis.International journal of general medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Global diabetes rates are rising sharply, driving a parallel increase in diabetic kidney disease (DKD) - a key diabetic complication. This trend poses mounting public health and economic burdens worldwide. Current therapies remain inadequate, making DKD progression a pressing unmet need. This review aims to assess the efficacy and molecular mechanisms of food-medicine homologous herbs for DKD treatment. Methods: A comprehensive literature search was conducted across multiple databases (PubMed, Web of Science, Cochrane Library, and Embase) from inception to March 2025, using keywords including "diabetic kidney disease", and "traditional Chinese medicine". The search was meticulously designed to cover relevant research extensively. Data extraction focused on herb names, bioactive compounds, experimental models, therapeutic effects, and molecular targets. Findings: This review highlights 29 food-medicine homologous herbs with proven safety and efficacy in DKD. These herbs alleviate immune-inflammatory responses by modulating NF-κB, interleukins, TNF-α, chemokines, and adhesion molecules. They also reduce mitochondrial and non-mitochondrial ROS production, improving oxidative stress via Keap1/Nrf2/ARE, AMPK/SIRT, and NF-κB pathways. Renal fibrosis is suppressed through targeting fibrosis markers and regulating TGF-β/Smad and Notch signaling. Additionally, these herbs inhibit the AGEs/RAGE axis, correct gut dysbiosis, reduce apoptosis, activate autophagy, inhibit ferroptosis, and modulate microRNAs, collectively exerting renoprotective effects in DKD. Conclusions: Food-medicine homologous herbs demonstrate properties that align well with medical nutrition therapy principles, offering novel adjunctive therapeutic options for DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.